Last reviewed 2026-05-19 · How we verify

AHZANTIVE (AFLIBERCEPT-MRBB)

FORMYCON AG · FDA-approved approved ✓ Verified May 2026 Quality 9/100

AHZANTIVE (generic name: AFLIBERCEPT-MRBB) is a drug developed by FORMYCON AG. It is currently FDA-approved.

Aflibercept is a protein-based inhibitor of vascular endothelial growth factor A, long form. It belongs to the drug class of inhibitors and works by modulating the activity of vascular endothelial growth factor A.

At a glance

Generic name	AFLIBERCEPT-MRBB
Sponsor	FORMYCON AG
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

Conjunctival hemorrhage
Eye pain
Cataract
Vitreous detachment
Vitreous floaters
Intraocular pressure increased
Ocular hyperemia
Corneal epithelium defect
Detachment of the retinal pigment epithelium
Injection site pain
Foreign body sensation in eyes
Lacrimation increased

Serious adverse events

Endophthalmitis
Retinal detachment
Retinal tear
Hypersensitivity

Key clinical trials

An Open-Label, Multi-Center, Single-Arm Study to Evaluate the Ocular Safety and Usability of FYB203 Pre-filled Syringe (PFS) (Phase 4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AHZANTIVE CI brief — competitive landscape report
AHZANTIVE updates RSS · CI watch RSS
FORMYCON AG portfolio CI

Frequently asked questions about AHZANTIVE

What is AHZANTIVE?

AHZANTIVE (AFLIBERCEPT-MRBB) is a pharmaceutical drug developed by FORMYCON AG.

Who makes AHZANTIVE?

AHZANTIVE is developed and marketed by FORMYCON AG (see full FORMYCON AG pipeline at /company/formycon-ag).

What is the generic name of AHZANTIVE?

AFLIBERCEPT-MRBB is the generic (nonproprietary) name of AHZANTIVE.

What development phase is AHZANTIVE in?

AHZANTIVE is FDA-approved (marketed).

What are the side effects of AHZANTIVE?

Common side effects of AHZANTIVE include Conjunctival hemorrhage, Eye pain, Cataract, Vitreous detachment, Vitreous floaters, Intraocular pressure increased. Serious adverse events: Endophthalmitis, Retinal detachment, Retinal tear, Hypersensitivity.

Manufacturer: FORMYCON AG — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing